Amylyx Pharmaceuticals, Inc. (AMLX) · Aug 18, 2026 · Other events

Amylyx clears Phase 3 LUCIDITY endpoints, strengthening avexitide’s FDA path

Above the bar — Primary endpoint met; 55% reduction in composite Level 2/3 events, p=0.000003

Avexitide delivered a 55% placebo-adjusted reduction in serious hypoglycemic events and met every secondary endpoint, clearing the key clinical hurdle.

The trial’s success bar was the FDA-agreed reduction in hypoglycemic events, and Amylyx cleared it decisively. The standing setup already included encouraging prior avexitide data and a Phase 3 readout expected in the third quarter of 2026, so a positive direction was not wholly unexpected. The filing reports a 55% reduction versus placebo in the composite of Level 2 and Level 3 events, with a rate ratio of 0.45 and p=0.000003. 〔0〕 (Primary endpoint slide)

MeasureLUCIDITY result
Participants78
Composite Level 2/3 event reduction vs. placebo55%
Rate ratio0.45
95% confidence interval0.32–0.63
P-value0.000003
Double-blind treatment completionMore than 90%

The breadth of the result matters more than the headline percentage. All secondary endpoints also met statistical significance, covering Level 2 events measured by both self-monitoring blood glucose and continuous glucose monitoring, as well as Level 3 events. 〔1〕 That consistency reduces the risk that the primary result was driven by one narrow measurement approach.

Safety did not introduce an obvious offset in the topline readout. Through 16 weeks, adverse events were generally mild or moderate, and the filing reports no treatment-related serious adverse events; the most common issues were diarrhea and injection-site reactions. 〔2〕 The dataset is still small at 78 participants and topline-only, so regulatory review, durability, labeling, and commercial execution remain unresolved—but the central clinical hurdle has been cleared.

Net: this is better than merely confirming a positive setup. Prior studies had made efficacy plausible, but a statistically strong Phase 3 result across the primary and every secondary endpoint materially strengthens the case for an NDA and potential 2027 commercialization. The filing says the company expects to submit the NDA by the end of 2026, making regulatory execution the next major test. (Regulatory submission timeline) 〔3〕

What to watch next

NDA submission to the FDA, expected by year-end 2026

Original filing on SEC EDGAR

More Amylyx Pharmaceuticals, Inc. news

Amylyx clears Phase 3 LUCIDITY endpoints, strengthening avexitide’s FDA path | AMLX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.